Course of antidepressant treatment with tricyclic versus selective serotonin reuptake inhibitor agents: A comparison in managed care and fee-for-service environments

American Journal of Managed Care

Volumn 3, Issue 3, 1997, Pages 453-465

  Fairman, Kathleen A ^a   Teitelbaum, Fred ^a   Drevets, Wayne C ^b   Engquist, Gretchen ^c   Kreisman, Jerold J ^d   Norusis, Marija J ^e  

^a Express Scripts   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Engquist Pelrine and Powell Inc   (United States)

^d SSM Weight Loss Institute   (United States)

^e Norusis Statistical Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DEPRESSION; DOSE RESPONSE; DRUG COST; DRUG USE; ECONOMICS; FEMALE; HEALTH INSURANCE; HUMAN; INSURANCE; MALE; MEDICAL FEE; MIDDLE AGED; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; DRUG UTILIZATION REVIEW; FEE-FOR-SERVICE PLANS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; REGRESSION ANALYSIS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0031090335     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Regier DA, Hirschfeld RMA, Goodwin FK, Burke JD, Lazar JB, Judd LL. The NIMH Depression Awareness, Recognition and Treatment Program: Structure, aims and scientific basis. Am J Psychiatry 1988;145:1351-1357.
2. Katon W, VonKorff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76.
3. Keller MB, Klerman GL, Lavori PW, Fawcett JA, Coryell W, Endicott J. Treatment received by depressed patients. JAMA 1982;248:1848-1855.
4. Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;43:458-466.
5. Wells KB, Katon W, Rogers B, Camp P. Use of minor tranquilizers and antidepressant medications by depressed outpatients: Results from the Medical Outcomes Study. Am J Psychiatry 1994;151:694-700.
6. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994;97(6A suppl):24S-32S.
7. Lin EHB, VonKorff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
8. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM, Gross LS. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990;51(6 suppl):60-69.
9. Pollack MH, Rosenbaum JF. Management of antidepressant-induced side effects: A practical guide for the clinician. J Clin Psychiatry 1987;48:3-8.
10. Stokes PE. Fluoxetine: A five-year review. Clin Ther 1993;15:216-243.
11. Schweizer E, Rickels K, Uhlenhuth EH. Issues in the long-term treatment of anxiety disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press Ltd.;1995:1349-1359.
12. Zohar J, Zohar-Kadouch RC, Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 1992;43:210-218.
13. Boyer WF, Feighner JP. An overview of paroxetine. J Clin Psychiatry 1992;53(2 suppl):3-6.
14. Dechant KL, Clissold SP. Paroxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225-253.
15. Dunbar GC. Paroxetine in the elderly: A comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology 1995;51:137-144.
16. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53.
17. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. Int Clin Psychopharmacol 1995;9(4 suppl):33-40.
18. Murdoch D, McTavish D. Sertraline: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992;44:604-624.
19. Tollefson GD, Holman SL, Sayler ME, Potvin JH. Fluoxetine, placebo and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994;55:50-59.
20. Workman EA, Short DD. Atypical antidepressants versus imipramine in the treatment of major depression: A metaanalysis. J Clin Psychiatry 1993;54:5-12.
21. Franco K, Tamburino M, Campbell N, Zrull J, Evans C, Bronson D. The added costs of depression to medical care. PharmacoEconomics 1995;7:284-291.
22. Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol 1994;9:229-243.
23. Thompson C. Bridging the gap between psychiatric practice and primary care. Int Clin Psychopharmacol 1992;7(2 suppl):31-36.
24. Zetin M, Hansen J. Rational antidepressant selection. Compr Ther. 1994;20(4):209-223.
25. Gram L. Fluoxetine. Comprehensive Therapy, N Engl J Med 1994;331:1354-1361.
26. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994;182:547-551.
27. Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br Med J 1996;168:404-409.
28. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. Br Med J 1993;306:683-687.
29. Fawcett J. Compliance: Definitions and key issues. J Clin Psychiatry 1995;56(1 suppl):4-8.
30. Katon W, VonKorff M, Lin E, et al. Collaborative management to achieve treatment guidelines: Impact on depression in primary care. JAMA 1995;273:1026-1031.
31. Lebowitz BD, Martinez RA, Niederehe G, et al. NIMH/MacArthur Foundation Workshop Report: Treatment of depression in late life. Psychopharmacol Bull 1995;31:185-202.
32. Katzelnick DJ, Kobak KA, Jefferson JW, Greist JH, Henk HJ. Prescribing patterns of antidepressant medications for depression in a HMO. Formulary 1996;31:374-388.
33. Sclar DA, Robjson LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther 1994;16:715-730.
34. Simon GE, VonKorff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408.
35. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine versus tricyclic antidepressants. JAMA 1996;275:1897-1902.
36. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633-642.
37. PDR Generics. Montvale, NJ: Medical Economics;1995.
38. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety 1994;10:18-46.
39. SPSS for Windows NT (Version 7.0) SPSS, Chicago, IL.
40. Minum EW. Statistical Reasoning in Psychology and Education. 2nd ed. New York:John Wiley & Sons, 1978:277.
41. Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990;51(6 suppl):3-11.
42. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995;52:850-856.
43. Plotkin DA, Gerson SC, Jarvik LF. Antidepressant drug treatment in the elderly. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1149-1158.
44. American Psychiatric Association Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants - blood level measurements and clinical outcome: An APA task force report. Am J Psychiatry 1985;142:155-162.
45. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52(suppl):23-33.
46. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-418.
47. Norquist GS, Wells KB. How do HMOs reduce outpatient mental health care costs? Am J Psychiatry 1991;148:96-101.
48. Sturm R, Jackson CA, Meredith LS, et al. Mental health care utilization in prepaid and fee-for-service plans among depressed patients in the Medical Outcomes Study. Health Services Research 1995;30:319-340.
49. Wells KB, Manning WG, Benjamin B. Use of outpatient mental health services in HMO and fee-for-service plans: Results from a randomized controlled trial. Health Serv Res 1986;21:453-474.
50. Eisenberg L. Treating depression and anxiety in primary care: Closing the gap between knowledge and practice. N Engl J Med 1992;326:1080-1084.
51. Robinson P, Bush T, VonKorff M, et al. Primary care physician use of cognitive behavioral techniques with depressed patients. J Fam Pract 1995;40:352-357.
52. Sturm R, Meredith LA, Wells KB. Provider choice and continuity for the treatment of depression. Med Care 1996;34:723-734.
53. Brown JB, Shye D, McFarland B. The paradox of guideline implementation: How AHCPR's depression guideline was adapted at Kaiser Permanente Northwest Region. It Comm J Qual Improv 1995;21:5-21.